Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Nov;20(11):1337-1344.
doi: 10.1016/j.jcyt.2018.09.003. Epub 2018 Oct 14.

Off-label mesenchymal stromal cell treatment in two infants with severe bronchopulmonary dysplasia: clinical course and biomarkers profile

María Álvarez-Fuente  1 , Luis Arruza  2 , Paloma Lopez-Ortego  3 , Laura Moreno  4 , Manuel Ramírez-Orellana  5 , Carlos Labrandero  6 , África González  5 , Gustavo Melen  5 , Maria Jesús Del Cerro  7
Affiliations
Case Reports

Off-label mesenchymal stromal cell treatment in two infants with severe bronchopulmonary dysplasia: clinical course and biomarkers profile

María Álvarez-Fuente et al. Cytotherapy. 2018 Nov.

Abstract

Background: Bronchopulmonary dysplasia (BPD) is the most prevalent sequelae of premature birth, for which therapeutic options are currently limited. Mesenchymal stromal cells (MSCs) are a potential therapy for prevention or reversal of BPD.

Series of cases: We report on two infants with severe BPD in whom off-label treatment with repeated intravenous doses of allogeneic bone marrow-derived MSCs were administered. We analyzed the temporal profile of serum and tracheal cytokines and growth factors as well as safety, tolerability and clinical response. The administration of repeated intravenous doses of MSCs in two human babies with severe and advanced BPD was feasible and safe and was associated with a decrease of pro-inflammatory molecules and lung injury biomarkers. Both patients were at very advanced stages of BPD with very severe lung fibrosis and did not survive the disease.

Conclusions: MSCs are a promising therapy for BPD, but they should be administered in early stages of the disease.

Keywords: bronchopulmonary dysplasia; chronic lung disease of the newborn; mesenchymal stromal cells; molecular biomarkers; preterm newborns; pulmonary vascular disease; regenerative medicine; very low–birth weight infants.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types

LinkOut - more resources

  NODES
admin 4
twitter 2